EML4 and non-small cell lung carcinoma: For example, although most patients with echinoderm microtubule-associated protein-like 4 (EML4)-ALK positive non-small cell lung cancer (NSCLC) derive advantages from treatment with ALK inhibitors, the clinical response to these drugs varies significantly among such individuals9.